Seoul Pharma Co., Ltd
Financials
Valuation Metrics
Seoul Pharma Co., Ltd's Market Cap is ₩230B. At end of 2025 it was ₩359B. Ranked #2254 of 2,421 in KR market (top 93%), #1489 of 1,640 on KOSDAQ (top 91%), #223 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 22.98B KRW | KR#2,254/2,421 Sec#223/231 |
| Revenue | 51.08B KRW | KR#1,777/2,421 Sec#120/231 |
| Net Income | 1.74B KRW | KR#1,434/2,421 Sec#98/231 |
| Total Assets | 68.24B KRW | KR#2,029/2,421 Sec#170/231 |
| Net Assets | 40.54B KRW | KR#2,038/2,421 Sec#180/231 |
| Employees | 176 | KR#1,185/2,421 Sec#97/231 |
| Value | ||
| P/E | 13.22x | KR#979/2,421 Sec#54/231 |
| P/B | 0.57x | KR#923/2,421 Sec#47/231 |
| P/S | 0.45x | KR#847/2,421 Sec#35/231 |
| FCF Yield | 4.46% | KR#885/2,421 Sec#51/231 |
| Profitability | ||
| ROE | 4.29% | KR#1,182/2,421 Sec#82/231 |
| ROA | 2.55% | KR#1,115/2,421 Sec#83/231 |
| Op. Margin | -1.53% | KR#1,717/2,421 Sec#116/231 |
| Revenue Growth | -2.14% | KR#1,636/2,421 Sec#159/231 |
| Financial Health | ||
| Debt Ratio | 68.32% | KR#1,201/2,421 Sec#145/231 |
| Total Debt | 13.00B KRW | KR#1,539/2,421 Sec#134/231 |
| FCF | 1.02B KRW | KR#1,146/2,421 Sec#86/231 |
| Cash | 16.82B KRW | KR#1,363/2,421 Sec#107/231 |
| Current Ratio | 1.45x | KR#1,247/2,421 Sec#133/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -38.79% | KR#1,805/2,421 Sec#148/231 |
| 1M Return | 0.46% | KR#1,180/2,421 Sec#89/231 |
| From 52W High | -40.45% | KR#948/2,421 Sec#65/231 |
| 1Y MDD | -40.19% | KR#589/2,421 Sec#41/231 |
| Trading | ||
| Volume | 1,319 shares | KR#2,306/2,421 Sec#222/231 |
| Trading Value | 2.6M KRW | KR#2,360/2,421 Sec#225/231 |
| Foreign Own. | 2.17% | KR#1,571/2,421 Sec#149/231 |
| Per Share | ||
| EPS | 149 KRW | KR#1,362/2,421 Sec#90/231 |
| BPS | 3,477 KRW | KR#1,759/2,421 Sec#130/231 |
Company Info
Established in 1985 and listed on KOSDAQ in 2000, this pharmaceutical company produces drugs such as antihypertensive Ator, stroke treatment Plavel, and obesity treatment Weltmin. It leverages SmartFilm® Technology for oral disintegrating film manufacturing, supplying products to partners like Pfizer Korea. The company is preparing new and generic drugs for chronic diseases like hyperlipidemia, gastroesophageal reflux disease, and diabetes to expand market share, with its new Osong plant establishing a foundation for global expansion. Seoul Pharma is headquartered in Cheongju-si, Chungcheongbuk-do.